Lindorff and Intrum Justitia turns together – E24

Dynavax says FDA rejects its hepatitis B vaccine

The U. S. Food and Drug Administration rejected Dynavax Technologies Corp.’s marketing application for its hepatitis B vaccine, Heplisav-B, for the second time in three years, sending the company’s shares tumbling 71 percent in premarket trade.

www.reuters.com